India’s patent office rejects a patent application linked to a drug-resistant tuberculosis treatment regimen developed by the U.S.-based Global Alliance for TB Drug Development (TB Alliance). The decision follows objections from patient and civil society groups, who argue the claimed combination is already known and should not be protected by patent rights.
Two outlets describe the ruling as a step that could support more affordable access to medicines used in the BPaL regimen—bedaquiline, pretomanid and linezolid—which is presented as an all-oral, shorter-course alternative for eligible drug-resistant TB patients. The Hindu and other reports also note that civil society groups urge TB Alliance to withdraw related patent claims in other countries.
Coverage also reflects differing emphasis: some focus on the legal and technical reasons for rejection under Indian patent law, while others highlight the implications for patient access and affordability. While outlets broadly agree on the rejection and the opposition from patient groups, they vary in how much background they provide on the regimen and on public health figures.
